Lackluster Zytiga combination data unlikely to boost Provenge commercial case
This article was originally published in Scrip
Executive Summary
Dendreon's attempts to persuade physicians to prescribe its expensive personalized immunotherapy Provenge (sipuleucel-T) instead of the J&J's Zytiga (abiraterone acetate) for metastatic castrate-resistant prostate cancer (mCRPC) are so far wholly unimpressive.